NCT01273493View on ClinicalTrials.gov

A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Neoplasm MetastasesHepatic Insufficiency
Interventions
DRUG

Trabectedin

Trabectedin 0.58 or 1.3 mg/m\^2 (or adjusted dose) i.v. will be administered on Day 1.

DRUG

Dexamethasone

Dexamethasone will be administered as 20 mg/m\^2, 30 minutes prior to trabectedin.

Trial Locations (11)

Unknown

Scottsdale

Detroit

New York

Philadelphia

Salt Lake City

Tacoma

Edegem

Wilrijk

Edmonton

Barcelona

Madrid

Sponsors

Collaborators (1)

PharmaMar
All Listed Sponsors
collaborator

PharmaMar

INDUSTRY

lead

Janssen Research & Development, LLC

INDUSTRY